Ozempic, or semaglutide, is just one drug in a growing class of medications known as GLP-1 agonists
Across n=95 trial participants, the authors reported over 20 weeks a weight reduction of -15.7 percent (cagrilintide 1.2 mg) and -17.1 percent (cagrilintide 2.4 mg) in combination with semaglutide 2.4 mg, compared with -9.8 percent on semaglutide alone
You should keep in mind that, as is the case with any type of infusion, IV procedures are never completely risk-free
To view a copy of this licence, visit About this article Cite this article Peri, R.V., Anchan, H., Jonnalagadda, K
New formulations use protective technologies that allow the medication to survive the digestive process and be absorbed effectivelythough with some important requirements around timing and dosing